Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.42 |
| ▸ | BCR | P11274 | 14/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581852 | 0.79 | IDH1 (0.44) | — | |
| SCHEMBL4581848 | 0.79 | IDH1 (0.44) | — | |
| SCHEMBL4591653 | 0.79 | HDAC1 (0.40) | HDAC1HDAC8HDAC6SCN9ARPS6KA5 | |
| SCHEMBL10506257 | 0.71 | RXFP1 (0.44) | — | |
| SCHEMBL4580829 | 0.69 | HDAC1 (0.42) | HDAC1HDAC8HDAC6MAPT | |
| SCHEMBL4581847 | 0.68 | HDAC1 (0.43) | HDAC1HDAC8HDAC6MAPT | |
| SCHEMBL4581690 | 0.68 | TRPV1 (0.42) | HDAC1HDAC8HDAC6MAPT | |
| SCHEMBL21361176 | 0.67 | CDK4 (0.40) | ABL1BCRMAPT | |
| SCHEMBL4580841 | 0.67 | IDH1 (0.42) | HDAC1HDAC8HDAC6 | |
| SCHEMBL4580975 | 0.67 | IKBKB (0.41) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | ABL1 32/4885BCR 63/4885HDAC1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.